TABLE 1.
Diabetes drug | Model | Species | Treatment | Effects | References |
Biguanide | OGD | bEND.3 cells | Metformin | Inhibition of inflammatory signaling pathways | Liu et al., 2014 |
Biguanide | OGD | Rat cortical neurons | Metformin | Pre-treatment of neurons alleviated OGD/R-induced injury | Meng et al., 2016 |
Biguanide | OGD | Primary rat fetal-derived astrocytes | Metformin | Improve cell viability via reduction of apoptosis mechanisms | Gabryel and Liber, 2018 |
Biguanide | OGD | PC-12 cells | Metformin | Reduce cell death under OGD/R condition and attenuation of ROS generation | Mohammad Alizadeh et al., 2018 |
Biguanide | OGD | Primary cortical and hippocampal neurons | Metformin | Moderate improvement of cell viability | Mielke et al., 2006 |
TZD | OGD | Rat hippocampal slices | NP00111 Rosiglitazone | Protection against OGD by a mechanism related to phosphorylation of ERK1/2 via activation of PPARγ | Rosa et al., 2008 |
TZD | OGD | Primary cultured astrocytes | Pioglitazone | Protective effects with inhibition of pyroptosis mechanism induced by the OGD | Xia et al., 2018 |
DPP4 | OGD | HBMVECs | Alogliptin | Protection against OGD and increasing of permeability in human brain vascular cells | Hao et al., 2019 |
Incretin GLP1-R agonist | OGD | Rat cortical neurons | Exendin-4 | Protects neurons through PKA pathway | Wang M.-D. et al., 2012 |
Incretin GLP1-R agonist | OGD | Rat cortical neurons | Liraglutide | Neuroprotective action with reduction of apoptosis and ROS via activation of the PI3K/AKT and MAPK pathways | Zhu et al., 2016 |
Incretin GLP1-R agonist | OGD | Mouse cortical neurons | DMB | Neuroprotection with anti-apoptotic effects, mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway | Zhang et al., 2016 |
Sulfonylurea | HI P10 | Rat | Glibenclamide | No effects on severe HI model Improvement neurological functions in moderate HI model | Zhou et al., 2009 |
TZD | HI 8W | Ob/Ob mouse | Darglitazone | Reduction of the infarct size and neuroinflammation response | Kumari et al., 2010 |
Biguanide | HI P8 | Mouse | Metformin | Activation of endogenous NPCs, promoting their migration and differentiation in the injured brain Restoration of sensory-motor function | Dadwal et al., 2015 |
Biguanide | HI P3 | Rat | Metformin | Attenuation of cognitive impairments Induction of OPCs proliferation reducing myelination damage | Qi et al., 2017 |
Biguanide | HI P7 | Rat | Metformin | Attenuation brain infarct and oedema Inhibition of neuronal apoptosis, and neuroinflammation + amelioration of the blood brain barrier breakdown | Fang et al., 2017 |
Biguanide | HI P8 | Mouse | Metformin | Sex-dependent effects on proliferation but increases neurogenesis in both sexes; rescues cognitive deficits in adult females | Ruddy et al., 2019 |
Incretin GLP1-R agonist | HI P7/P10 | Mouse | Exendin-4** | Neuroprotective effect alone or in combination with therapeutic hypothermia | Rocha-Ferreira et al., 2018 |
Incretin GLP1-R agonist | HI P7 | Rat | Liraglutide | Inhibited apoptosis and promoted neuronal survival; PI3K/Akt pathway involved | Zeng et al., 2020 |
In vitro model with OGD on different cell types and in vivo models with HI at different stage of age. **Only study using combination with hypothermia.